In These Times, February 3, 2016. It’s been called the first “Viagra for women” and hailed as a health breakthrough. But Addyi (generic name flibanserin) is sparking ire just as it claims to spark desire. Since the FDA approved Addyi in August 2015, feminist debate on these questions has raged.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Panel Recommends FDA Approve Implant to Treat Opiate Addiction
USA Today, January 12, 2016. An advisory committee recommended Tuesday that the Food and Drug Administration (FDA) approve an implant designed to reduce addicts’ cravings for heroin or prescription painkillers.
Read More »Partisan Split Threatens Progress on Bill to Speed Drug Approvals
STAT, February 1, 2016. When Republican senators overseeing legislation to accelerate medical treatments said they would chop the bill into parts, Democrats put on a good face.
Read More »Did FDA Screw Up Its Reporting of Essure Deaths?
QMED, February 7, 2016. An independent analysis of FDA MAUDE data shows 303 fetal deaths related to the Bayer contraceptive medical device, but FDA itself has only reported five. A U.S. congressman is officially demanding answers while also alleging that some doctors implanting the device received illegal kickbacks.
Read More »FDA Faulted for Problems With Drug Tracking
New York Times, January 14, 2016. Federal investigators said Thursday that there were flaws in the way the Food and Drug Administration tracked drugs after they came to market, raising questions about the agency’s effectiveness as the country’s main drug overseer.
Read More »